氯吡格雷抵抗机制的研究进展及临床处理策略
PDF下载 (442)李晓静 1,陈晓敏 2*.氯吡格雷抵抗机制的研究进展及临床处理策略[J].宁波大学学报(理工版),2013,26(04):111-114.DOI:
LI Xiao-jing 1,CHEN Xiao-min 2*.Research Progress: Mechanisms and Intervention Strategies of Clopidogrel Resistance[J].Journal of Ningbo University(Natural Science & Engineering Edition),2013,26(04):111-114.DOI:
| Title: | Research Progress: Mechanisms and Intervention Strategies of Clopidogrel Resistance |
| 作者: | 李晓静 1, 陈晓敏 2* |
| Author(s): | LI Xiao-jing 1, CHEN Xiao-min 2* |
| 关键词: | 氯吡格雷抵抗; 单核苷酸多态性; 血小板聚集; 临床干预 |
| Keywords: | clopidogrel resistance; single nucleotide polymorphism; platelet aggregation; clinical intervention |
| 分类号: | R54 |
| 文献标识码: | A |
| 摘要: | 冠心病患者尽管接受了标准的氯吡格雷治疗, 但仍有一部分患者对氯吡咯雷表现为低反应甚至无反应, 称为氯吡格雷抵抗. 导致这种抵抗现象的可能原因包括患者个体的基因多态性和药物之间的相互作用等. 临床处理的主要对策有提高氯吡格雷的给药剂量和采用新型药物等. 笔者就现有的临床研究证据对氯吡格雷抵抗的定义、发生机制及临床干预策略进行了综述. |
| Abstract: | Despite the standard dose of clopidogrel used in treatment of the patients with coronary heart disease, many studies have found that some patients show low response even no response to clopidogrel, which is defined as clopidogrel resistance. In this paper, we explore the mechanism of clopidogrel resistance, and suspect that the clopidogrel resistance may be caused by the individual gene polymorphism, drug interactions and so on. The countermeasures to the clopidogrel resistance include increasing the clopidogrel dosage, use of new drugs, etc. The definition and triggering mechanism of the clopidogrel resistance are also reviewed in this report. |
| 参考文献 /References: | [1] Graeme J H, John W E. Aspirin resistance[J]. Lancet 2006, 367:606-617. [2] Gurbel P A, Tantry U S. Clopidogrel resistance[J]. Thromb Res, 2007, 120:311-321. [3] Price M J, Berger P B, Teirstein P S, et al. Standard-vs highdose clopidogrel based on platelet function testing after percutaneous coronary intervention: The gravitas randomized trial[J]. JAMA, 2011, 305:1097-1105. [4] Paul A G, Kevin P B, Bonnie L H, et al. Clopidogrel for coronary stenting response variability, drug resistance, and the effect of pretreatment platelet reactivity[J]. Circulation, 2003, 107:2908-2913. [5] Soffer D, Moussa I, Harjai K J, et al. Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: Do we need more aggressive dosing reginens in unstabled angina[J]. Catheter Cardiovasc Interv, 2003, 59:21-25. [6] Lepantalo A, Virtanen K S, Hekkila J, et al. Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions[J]. EurHeart J, 2004, 25(6):476-483. [7] Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite[J]. Drug Metab Dispos, 2010, 38:92-99. [8] Mega J L, Close S L, Wiviott S D, et al. Cytochrome p-450 polymorphisms and response to clopidogrel[J]. N Engl J Med, 2009, 360:354-362. [9] Fontana P, Dupont A, Gandrille S, et al. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects[J]. Circulation, 2003, 108:989-995. [10] Gilard M, Arnaud B, Le G G, et al. Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin[J]. Thromb Haemost, 2006, 4:2508-2509. [11] Lau W C, Waskell L A, Watkins P B, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: A new drug-drug interaction[J]. Circulation, 2003, 107:32-37. [12] Hong S J, Park J Y, Kim K A, et al. Comparison of low vs moderate dose of atorvastatin in clopidogrel resistance after coronary stenting in Korean patients with acute coronary syndrome[J]. Circ J, 2009, 73:1111-1118. [13] Geisler T, Zürn C, Paterok M, et al. Statins do not adversely affect post-interventional residual platelet aggregation and outcomes in patients undergoing coronary stenting treated by dual antiplatelet therapy[J]. Eur Heart J, 2008, 29:1635-1643. [14] Mehta S R, Bassand J P, Chrolavicius S, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes[J]. N Engl J Med, 2010, 363:930-942. [15] Ainterdinova D K, Udovichenko A E, Sulinov V A. Resistance to anteplatelet drugs in patients with non ST elevation acute coronary sydrome[J]. Kardiologiia, 2008, 48(6):35-39. [16] Kastrati A, Mehilli J, Neumann F J, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial[J]. JAMA, 2006, 295(13):1531-1538. [17] Kushner F G, hand M, Smith S C, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/ AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): A report of the American college of cardiology foundation/American heart association task force on practice guedelines[J]. J Am Coll Cardiol, 2009, 54:2205-2241. [18] Montalescot G, Sideris G, Cohen R, et al. Prasugrel compared with high-dose clopidogrel in acute coronary syndrome[J]. Thromb Haemost, 2010, 103:213-223. [19] Pena A, Collet J P, Hulot J S, et al. Can we override clopidogrel resistance[J]. Circulation, 2009, 119:2854-2857. [20] Wallentin L, Becker R C, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J]. N Engl J Med, 2009, 361:1045-1057. [21] Han Y, Li Y, Wang S, et al. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: A randomized, controlled study[J]. Am Heart J, 2009, 157:733-739. |
| 备注/Memo: | 收稿日期: 2013-06-19. 第一作者: 李晓静（1984-）, 女, 浙江宁波人, 在读硕士研究生, 主要研究方向: 心血管内科. E-mail: reta_lee@hotmail.com *通信作者: 陈晓敏（1963-）, 男, 浙江宁波人, 主任医师, 主要研究方向: 心血管内科. E-mail: chxmin@hotmail.com 宁波大学学报（理工版）网址：http://journallg.nbu.edu.cn/ |
